The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026.
Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027, in a bid to make the treatments more accessible to patients with insurance coverage.
The obesity injection Wegovy, its new pill counterpart, the diabetes shot Ozempic and the oral diabetes drug Rybelsus will have a new lower list price of $675 per month starting on Jan. 1, 2027. The Wegovy medicines both currently have list prices of around $1,350 per month, while the diabetes drugs have list prices of around $1,027 per month.
For the first time, Novo said its price cuts are targeting insured patients whose out-of-pocket costs are linked to list prices, such as people with high-deductible health plans or coinsurance benefit designs.
"Both of these patient populations should, beginning [in 2027], see a benefit with lower out-of-pocket burdens," Jamey Millar, the company's head of U.S. operations, told CNBC in an interview.
He added that Novo expects improvements in access and uptake among patients in the commercial insurance market, though the company is not giving any specific expectations.
The move could help Novo compete better with Eli Lilly , which now holds the majority share in the blockbuster GLP-1 market. Lilly's more effective drugs and earlier foray into the direct-to-consumer space have allowed it to take the lead in the space, but the company has yet to significantly lower the U.S. list prices of its medicines.
— Source: CNBC Business (https://www.cnbc.com/2026/02/24/novo-nordisk-to-slash-wegovy-ozempic-us-list-prices-by-up-to-50percent.html)
